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A B S T R A C T
Stress granules (SGs) are dynamic cytoplasmic aggregates of translationally silenced mRNAs that assemble in
response to environmental stress. SGs appear to play an important role in antiviral innate immunity and many
viruses have evolved to block or subvert SGs components for their own beneﬁt. Here, we demonstrate that
intracellular Ebola virus (EBOV) replication and transcription-competent virus like particles (trVLP) infection
does not lead to SG assembly but leads to a blockade to Arsenite-induced SG assembly. Moreover we show that
EBOV VP35 represses the assembly of canonical and non-canonical SGs induced by a variety of pharmacological
stresses. This SG blockade requires, at least in part, the C-terminal domain of VP35. Furthermore, results from
our co-immunoprecipitation studies indicate that VP35 interacts with multiple SG components, including
G3BP1, eIF3 and eEF2 through a stress- and RNA-independent mechanism. These data suggest a novel function
for EBOV VP35 in the repression of SG assembly.
1. Introduction
Ebola virus (EBOV) is a single-stranded, negative sense RNA virus
of the family Filoviridae that produces a severe haemorrhagic fever
with high mortality rates in humans and primates. The EBOV outbreak
that started in 2014 was the largest registered since its discovery, with
more than 28,000 cases and an estimated 50% fatality rate. In January
2016, the World Health Organization (WHO) declared the end of
EBOV transmission in West Africa but noted that Guinea, Liberia and
Sierra Leone remain at high risk for additional small outbreaks. EBOV
can be transmitted from human to human through contact with
infectious body ﬂuids and currently there are no antiviral drugs or
post-exposure prophylaxis available (Martinez et al., 2015). For these
reasons, EBOV is recognized as a major threat to global health security
and work is performed under biosafety level 4 containment.
An EBOV infection is characterized by an aberrant innate immune
response and immunosuppression (Baize et al., 1999; Harcourt et al.,
1998, 1999; Sanchez et al., 2004; Towner et al., 2004). The multi-
functional protein VP35 has a critical function in innate immune
evasion by preventing the phosphorylation and dimerization of inter-
feron regulatory factor 3 (IRF-3) (Basler et al., 2003), inhibiting the
induction of IFN □/□ expression (Basler et al., 2003, 2000), blocking
the activation of protein kinase R (PKR) (Feng et al., 2007; Schumann
et al., 2009) and suppressing RNA silencing (Fabozzi et al., 2011;
Haasnoot et al., 2007). Additionally, EBOV VP35 plays crucial roles in
virus replication and assembly processes (Huang et al., 2002; Johnson
et al., 2006; Muhlberger et al., 1998; Noda et al., 2005). VP35
comprises an N-terminal oligomerization domain, which carries out
replication/structural roles and a C-terminal interferon inhibitory
domain (IID) that binds double-stranded RNA (dsRNA) and antag-
onizes type I IFN responses (Leung et al., 2009; Reid et al., 2005).
VP35 IID acts as a binding site for NP (nucleoprotein), is able to bind
the phosphate backbone of dsRNA through a central basic patch and
caps the ends of dsRNA via a hydrophobic pocket. The latter two
regions are distinct from each other and eﬀectively mask the viral RNA
to prevent activation of the RIG-I pathway and PKR, thus hampering
induction of the host antiviral state (Kimberlin et al., 2010; Leung
et al., 2009, 2010b). Moreover, VP35 can impede PKR activity and
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consequently decrease eukaryotic initiation factor 2α (eIF2α) phos-
phorylation (Feng et al., 2007; Schumann et al., 2009).
To cope with stressful conditions, including heat shock, oxidative
stress, nutrient deprivation or viral infection, eukaryotic cells activate
cellular kinases (HRI, GCN2, PKR and PERK) to phosphorylate the
initiation factor eIF2α. Phosphorylation of eIF2α impairs the formation
of the eIF2-GTP-tRNAMet ternary complex, which results in a rapid
block to global translation. Arresting protein translation initiation
causes the assembly of stress granules (SGs). SGs are dynamic
accumulations of stalled translation pre-initiation complexes that are
characterized by untranslated mRNAs, eukaryotic translation initiation
factors (eIF4E, eIF4G, eIF4A, eIF3, eIF2), the 40S ribosomal subunit
and numerous RNA-binding proteins including the poly(A) binding
protein (PABP), T-cell intracellular antigen 1 (TIA-1), TIA-1-related
protein (TIAR), and ras GTPase-activating protein-binding protein 1
(G3BP1) (Anderson and Kedersha, 2002; Buchan and Parker, 2009;
Jain et al., 2016; Kedersha et al., 2000; Tourriere et al., 2003). SGs
impart key regulatory measures on gene expression under stress
conditions and consequently, viruses have evolved to co-opt compo-
nents of SGs to promote their replication [reviewed in (Lloyd, 2013)].
Recently, SGs have been ascribed an important antiviral function,
which requires the activity of G3BP1, in order to bridge the stress
response and innate immunity (Reineke et al., 2015; Reineke and
Lloyd, 2015).
As EBOV VP35 plays important roles in controlling the host innate
immune response, we set out to explore whether VP35 could repress
SG assembly. Indeed, we found that EBOV trVLP infection impedes
SGs assembly, and that EBOV VP35 blocks the assembly of arsenite-
(Ars), Pateamine A- (PatA) and selenite- (Se) induced SGs but only
when the viral protein is expressed above an arbitrary concentration
threshold. We demonstrate that EBOV VP35 is able to interact with
several SG components, including eukaryotic elongation factor 2
(eEF2), eIF3 and G3BP1 via a stress- and RNA-independent mechan-
ism. Furthermore, we determined that the C-terminal domain of VP35,
which contains the IID and the dsRNA-binding domain, is necessary
for eﬃcient SG blockade.
2. Materials and methods
2.1. Cells, transfection and infection conditions
Green African monkey kidney (Vero) cells, human osteosarcoma-
derived U2OS containing G3BP1-GFP (a kind gift from Dr. Paul
Anderson, Harvard Medical School, (Ohn et al., 2008)) cells and 293
T cells (American Type Culture Collection; ATCC, Rockville, USA) were
maintained in Dulbecco's modiﬁed Eagle's medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) (HyClone) and 1%
penicillin/streptomycin (Life Technologies). Cells were transfected
using JetPrime (PolyPlus transfections), according to manufacturer's
instructions. Transfected cells were incubated for 24 h or otherwise
indicated before being stressed, as speciﬁed below. For each experi-
ment an average of 65% of cells were successfully transfected.
Cell-free Mahoney strain of poliovirus type 1 stocks were prepared
by de novo infection of 293T cells followed by three freeze-thaw cycles
as described in (Monette et al., 2013). Vero cells were transfected with
VP35-GFP and at 24 h post-transfection, cells were washed and
infected with poliovirus at an m.o.i. of 5. Titre was determined
empirically to obtain 100% infection (Monette et al., 2013). At 4 h
post-infection, cells were ﬁxed and permeabilized for indirect immuno-
ﬂuorescence.
2.2. Plasmids
The EBOV VP35 cDNA was ampliﬁed from pCAGGS-HA-VP35(R)
(Basler et al., 2003) and cloned into Myc pcDNA3.1/Zeo (MYC-VP35)
and pEGFP-C1 (GFP-VP35) (generously provided by Dr. Rongtuan
Lin). The VP35 truncation mutants were previously described in
(Kirchdoerfer et al., 2015) (a kind gift from Dr. Erica Saphire).
G3BP1-GFP was provided by Dr. Imed Gallouzi (McGill University).
TIA-1-RFP was provided by Dr. Christina Vande Velde (Université de
Montréal). Plasmids for the Ebola Zaire (ZEBOV) mini-genome assay
(pCAGGS-NP, pCAGGS-VP35, pCAGGS-VP30, pCAGGS-L, p4cis-
vRNA-RLuc, pCAGGS-T7, and pCAGGS-Tim1) were provided by Drs.
Thomas Hoenen and Heinz Feldmann (NIH, NIAID, Bethesda).
2.3. Transcription- and replication-competent ZEBOV tetracistronic
trVLP system
This life cycle modeling system has been previously described in
(Hoenen et al., 2014; McCarthy et al., 2016). Brieﬂy, the tetracistronic
mini-genome encodes 3 of the 7 Ebola proteins (VP24, VP40 and
GP1,2) and a renilla luciferase (Rluc) reporter gene. Expression
plasmids for the remaining four Ebola nucleocapsid proteins (L, NP,
VP30 and VP35) were also included during transfection. To produce
transcription-competent virus like particles (trVLPs), 293 T cells were
seeded in DMEM containing 10% FBS and transfected with the viral
replication protein plasmids (L, NP, VP30, VP35), the tetracistronic
Ebola mini-genome and T7 polymerase, using the CalPhos Mammalian
Transfection Kit (Clontech Laboratories). After 24 h the medium was
replaced with DMEM containing 5% FBS. trVLPs were harvested from
the supernatant 3 days later and virus stocks were frozen at −80 °C.
For infection, Vero cells were seeded in DMEM supplemented with
10% FBS. Cells were transfected with the four viral replication protein
plasmids (L, NP, VP30, VP35), as well as Tim-1, to allow eﬃcient virus
binding and entry. Eighteen hours post-transfection, media was
removed and 100 μL of trVLP stock was diluted in 1.2 mL of DMEM
with 5% FBS, then added to the Vero cells. At 24 and 48 h post-
transfection (corresponding to 6 and 30 h after infection, respectively),
cells were treated with 500 μM Ars for 1hr, then ﬁxed and permeabi-
lized for indirect immunoﬂuorescence.
2.4. Stress induction
Stress was induced using 500 μM sodium Ars (NaAsO2; Sigma-
Aldrich) for 1 h, 300 nM PatA (a kind gift from Jerry Pelletier, McGill
University) for 1 h and 1 mM sodium selenite (Na2O3Se; Sigma-
Aldrich) for 2 h, unless otherwise stated.
2.5. Antibodies and reagents
Rabbit anti-G3BP1 (Santa Cruz Biotechnology) was used for
indirect immunoﬂuorescence microscopy at a dilution of 1:1000 and
for Western blotting at a dilution of 1:10,000; mouse anti-HA (Sigma)
was used for indirect immunoﬂuorescence microscopy at a dilution of
1:1000 and for Western blotting at a dilution of 1:10,000; goat anti-
eIF3 (Abcam) was used for indirect immunoﬂuorescence microscopy at
a dilution of 1:500 and for was used for Western blotting at a dilution
of 1:1000; goat anti-TIAR (Santa Cruz Biotechnology) was used for
indirect immunoﬂuorescence microscopy at a dilution of 1:500; rabbit
anti-Rluc (Abcam) was used for indirect immunoﬂuorescence micro-
scopy at a dilution of 1:500; rabbit anti-phospho-eIF2α (Ser51) (Cell
Signaling Technology) was used for Western blotting at a dilution of
1:1000; mouse anti-eIF2α (Cell Signaling Technology) was used for
Western blotting at a dilution of 1:1000; rabbit anti-eEF2 (Cell
Signaling Technology) was used for Western blotting at a dilution of
1:1000; mouse anti-GFP (Sigma) was used for Western blotting at a
dilution of 1:10,000; mouse anti-His (Santa Cruz Biotechnology) was
used for Western blotting at a dilution of 1:500; mouse anti-actin
(Abcam) was used for Western blotting at a dilution of 1:10,000 and
mouse anti-GAPDH (Abcam) was used for Western blotting at a
dilution of 1:5000. Horseradish peroxidase-conjugated secondary
antibodies were from Rockland Immunochemicals and used at a
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dilution of 1:5000, while AlexaFluor secondary antibodies were from
Life Technologies and used at a dilution of 1:500.
2.6. Western blot analysis
Cells were lysed in NP40 lysis buﬀer (50 mM Tris pH 7.4, 150 mM
NaCl, 0.5 mM EDTA, 0.5% NP40). Equal amounts of protein were
separated by SDS-PAGE, and transferred to a nitrocellulose membrane
(Bio-Rad). Membranes were probed with the indicated primary and
appropriate horseradish peroxidase-conjugated secondary antibodies.
Proteins were detected using Western Lightning Plus-ECL
(PerkinElmer). For quantitation, the pixel intensity for each band
was determined using the ImageJ program (NIH) and then normalized
to the indicated control.
2.7. Indirect immunoﬂuorescence
This method was previously described in (Vyboh et al., 2012).
Brieﬂy, cells were ﬁxed in 4% paraformaldehyde and permeabilized
with 0.2% Triton X-100. Primary antibodies were applied followed by
incubation in appropriate secondary antibody. Stained cells were
mounted in ProLong Gold Antifade Reagent with DAPI (Life
Technologies). Laser scanning confocal microscopy was performed
using a Leica DM16000B microscope equipped with a WaveFX
spinning disk confocal head (Quorum Technologies) and images were
acquired sequentially with a Hamamatsu ImageEM EM-charges
coupled device (CCD) camera. Imaging analyses were performed by
Imaris software v. 8.1.2 (Bitplane, Inc.). Confocal Z-stacks were
reconstructed into 3D animations using Imaris software 3D View
mode. The Surfaces function in Imaris was used to locate SGs
(G3BP1 signal) and EBOV VP35 based on background subtraction
and intensity thresholds. Negative isotype-matched antibody were used
to control for staining speciﬁcity.
2.8. Quantiﬁcation of stress granule positive cells
Twenty-four hours after transfection, cells were treated with
500 μM Ars for 1 h; 1 mM Se for 2 h or 50 nM PatA for 1 h and then
processed for immunoﬂuorescence as above. Transfected cells were
identiﬁed and a SG-positive cells was deﬁned as having at least 2 SGs as
determined by colocalized G3BP1 and TIAR puncta. The observed
phenotypes were representative of n =150 cells per conditions in each
experiment and SGs were deﬁned as G3BP1 foci (greater than 0.4 µm
(Emara et al., 2012)). The data are presented as the percent transfected
cells containing SGs.
2.9. Immunoprecipitation assay
Vero cells were transfected as described above. Brieﬂy, after
incubation without or with Ars, cells were solubilized with NP40 lysis
buﬀer and 500 μg of protein was immunoprecipitated with anti-GFP or
anti-MYC magnetic beads overnight as described by the manufacturer
(MLB). To digest RNA, 10 μg/mL of RNAse A was added to the
immunoprecipitation and incubated overnight at 4 °C.
2.10. In situ protein-protein interaction assay (DuoLink®)
G3BP1-GFP and MYC or MYC-VP35 DNA were co-transfected in
Vero cells seeded on 10 mm glass coverslips in 24-well plate and were
then ﬁxed (4% PFA), permeabilized (0.05% Triton X-100 in PBS,
10 min) and incubated with antibodies. Slides were processed for in
situ Proximity Ligation Assay (PLA) using the DUOLINK II In Situ kit
(Olink), according to the manufacturer's protocol to visualize MYC-
VP35/G3BP1-GFP heterodimers. Primary antibodies were mouse anti-
MYC (Abcam) and rabbit anti-GFP (Clontech), which were detected
using the DuoLink ® II Detection Reagent Red, Duolink® II PLA probe
anti-Mouse Minus and DuoLink® II PLA probe anti-rabbit Plus. To
check the speciﬁcity of the PLA signal, control experiments omitting
one of the primary antibodies were performed. Imaging was performed
as above. Nuclei were labeled with DAPI.
2.11. In vitro binding assay
1.5 μg of recombinant G3BP1-GST protein (Abnova) were incu-
bated in GST SpinTrap columns (GE healthcare) for 30 min at room
temperature. Columns were washed with TEN100 buﬀer (20 mM Tris
pH 7.4, 0.1 mM EDTA and 100 mM NaCl) to remove unbound G3BP1-
GST and subsequently incubated without or with 5.6 μg of recombinant
His-VP35 protein (Zinzula et al., 2009) for 2 h at 4 °C. Captured
complexes were washed 3 times with TEN100 buﬀer and elution was
performed using Elution Buﬀer (50 mM Tris-HCl, pH8 and 10 mM
glutathione). Samples were resolved by SDS-PAGE and probed using
antibodies against G3BP1 and His by Western blot analysis.
3. Results
3.1. EBOV infection does not induce SG assembly
Under stressful conditions, such as viral infection, SGs play an
important role in regulation of gene expression and consequently
viruses have evolved to co-opt SGs components to promote their own
replication and eliminate antiviral responses (Poblete-Duran et al.,
2016). We set out to determine whether or not EBOV infection trigger
the assembly of SGs, however, work with EBOV is restricted to BSL4
containment. A recently developed transcription- and replication-
competent virus-like particle (trVLP) system has made it possible to
study the EBOV life cycle under BSL2 conditions (Hoenen et al., 2014;
Watt et al., 2014). Vero cells were infected, as described in material and
methods, and SG assembly was evaluated by immunoﬂuorescence. In
trVLP-infected cells, 8% of cells displayed SG assembly, which was
comparable to the 10% of uninfected cells with SGs (Fig. 1A and B).
Interestingly the SG marker TIAR-1 was found to colocalize with VP35
in the viral inclusions. Oxidative stress inducing agents such as Ars
induce rapid SG assembly through the phosphorylation of eIF2α
(Kedersha et al., 1999; Ohn et al., 2008). As expected, the addition of
sodium arsenite (Ars) increased to 80% the amount of uninfected cells
having SGs, whereas only 37% of trVLP-infected cells demonstrated SG
assembly (Fig. 1A and B). These results indicate that EBOV-trVLP
infection does not induce SG assembly and suggest that EBOV has
evolved a mechanism by which to block the assembly of SGs.
3.2. EBOV VP35 blocks SG assembly
SGs are associated with silenced transcripts and many viruses are
known to subvert the function of these RNA granules for their
replicative advantage. As EBOV VP35 counteracts many cellular
antiviral activities, we investigated whether EBOV VP35 would inter-
fere with cellular SG assembly. We transfected African green monkey
kidney Vero cells with GFP or GFP-VP35-expressing plasmids and did
not treat or exposed to stress with sodium arsenite (Ars) and SG
assembly was monitored by indirect immunoﬂuorescence of G3BP1
and TIAR. In the absence of stress, 11.8% and 1.5% of GFP- and GFP-
VP35-transfected cells showed SG assembly, respectively (Fig. 1C and
D). In GFP-transfected Vero cells, Ars treatment induced abundant SG
assembly in 73.6% of cells, as demonstrated by colocalization of G3BP1
and TIAR in cytoplasmic foci of greater than 0.4 µm (Fig. 1C and D). In
VP35-expressing cells treated with Ars, TIAR was observed to have
shuttled from the nucleus to the cytoplasm but only accumulated in SG
foci that colocalized with G3BP1 in 23% of cells (Fig. 1C and D).
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3.3. EBOV VP35 blocks SG assembly independent of eIF2α
phosphorylation
PKR and other kinases phosphorylate eIF2α to block translation
initiation and regulate SG assembly (Kedersha et al., 1999; Ohn et al.,
2008). Because EBOV VP35 inhibits activation of PKR (Feng et al.,
2007; Schumann et al., 2009), we examined the phosphorylation status
of eIF2α in untreated and Ars treated cells expressing GFP-VP35.
Protein lysates were analyzed by Western blot using an antibody
speciﬁc for eIF2α phosphorylation at S51. As shown in Fig. 2A, very
little phosphorylation of eIF2α was detected in untreated cells expres-
sing GFP with a slight decrease in phospho-eIF2α being consistently
observed in GFP-VP35-transfected cells (Fig. 2A, lanes 1 and 2, and B).
As expected, high levels of eIF2α phosphorylation (2.7-fold increase)
were observed in extracts of GFP-expressing cells treated with Ars
(Fig. 2A, lane 3). A similar 3.1-fold increase in the levels of phospho-
eIF2α was detected in Ars stressed cells transfected with GFP-VP35
(Fig. 2A, lane 4, and B) as compared to untreated (Fig. 2A, lane 2, and
B). The amount of total eIF2α remained constant under all conditions
tested (Fig. 2A).
To conﬁrm the ability of EBOV VP35 to block SG assembly
independently of eIF2α phosphorylation, we treated the cells with
Pateamine A (PatA). PatA treatment induces SG assembly via an
eIF2α-independent mechanism by blocking translation initiation
through the hyperactivation of the eIF4A helicase, which disrupts the
eEF4F complex (Dang et al., 2006). GFP- or GFP-VP35-transfected
Vero cells were untreated or exposed to PatA and SG assembly was
monitored by indirect immunoﬂuorescence of G3BP1 and TIAR.
Fig. 1. EBOV blocks SG assembly. (A) Vero cells were infected, as described in material and methods, and 30 h after were left untreated or treated with 500 μM Ars for 45 min. Yellow
arrowheads indicate ZEBOV-negative cells, while pink arrowheads show ZEBOV-expressing cells. Scale bars are 10 µm. (B) Quantiﬁcation of uninfected or trVLP-infected Vero cells
containing SGs from Panel 1 A. Error bars represent the standard deviation from three independent experiments with at least 50 cells counted per treatment. Asterisks represent
statistically signiﬁcant diﬀerence between uninfected and trVLP-infected cells (Two-way ANOVA; p < 0.001). (C) Vero cells transfected with GFP or GFP-VP35 were untreated or
incubated with 500 μM Ars for 45 min. Cells were stained for G3BP1 (red) and TIAR (cyan). Yellow arrowheads indicate VP35-negative cells, while pink arrowheads show VP35-
expressing cells. Scale bars are 10 µm. (D) Quantiﬁcation of GFP- or GFP-VP35-transfected Vero cells containing SGs from Panel 1 C. Error bars represent the standard deviation from
three independent experiments with at least 150 cells counted per treatment. Asterisks represent statistically signiﬁcant diﬀerence between GFP and GFP-VP35-expressing cells (Two-
way ANOVA; p < 0.001).
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Similarly to Ars-treated cells (Fig. 1C and D), in PatA-treated cells
expressing GFP-VP35, SGs were observed in 21.5% of cells, as
compared to 69% of GFP-expressing cells having SGs (Fig. 2B and
C). Taken together, these results indicate that the VP35-mediated SG
blockade occurs via an eIF2α-independent mechanism.
3.4. EBOV VP35 blocks non-canonical SG assembly
Sodium selenite (Se), the commercially available version of sele-
nium, causes mRNA translational repression followed by the assembly
of non-canonical type II SGs, which diﬀer in size, localization,
composition (lack of eIF3) and mechanism of assembly from those
induced by Ars (Fujimura et al., 2012). We examined the ability of
VP35 to block the accumulation of non-canonical Se-induced SGs.
Osteosarcoma U2OS cells stably expressing GFP-G3BP1 (Ohn et al.,
2008) were mock- (pcDNA3.1) or MYC-VP35-transfected and subse-
quently stressed without or with Se. In untreated cells, 6% and 4.3% of
mock and MYC-VP35 transfected cells displayed SG, respectively
(Fig. 3A and B). As expected, Se treatment resulted in 73.4% of
mock-transfected cells being positive for SG assembly, whereas only
8.5% of MYC-VP35-expressing cells had SGs (Fig. 3A and B). To
further investigate the ability of VP35 to block the assembly of SGs
induced by other viral infection, we monitored the SGs formation
induced by Poliovirus (PV). In fact, it has been proposed that the
cleavage of eIF4G by the viral protease 2A is the main mechanism by
which PV induces SG assembly at early times during infection
(Dougherty et al., 2015). Vero cells were transfected with VP35-GFP
and 24 h later infected with the Mahoney strain of poliovirus type 1.
4 h post-infection the assembly of SGs was monitored by indirect
immunoﬂuorescence of TIAR. As shown in Supp. Fig. 1, TIAR
aggregates into cytoplasmic puncta in both VP35-GFP positive and
negative cells, indicating that VP35 is not able to counteract poliovirus-
triggered SG assembly. Taken together these results indicate that EBOV
VP35 blocks non-canonical SG assembly but not those induced by PV
infection.
3.5. A threshold level of EBOV VP35 is required to block SG assembly
To better understand the kinetics of the VP35-induced SG blockade,
we examined the assembly of SGs overtime. In untreated cells, as
expected, no SGs were visible and TIAR was predominantly localized to
the nucleus (Taupin et al., 1995), while GFP-VP35 was diﬀusely
distributed within the cytoplasm throughout the duration of the time
course (Supp. Fig. 2). Western blot analysis using an antibody against
GFP conﬁrmed that expression of GFP and GFP-VP35 increased over
time (Fig. 4B). At 3 h post-transfection the distribution of VP35,
expressed at detectable levels only in few cells, appeared punctate
and colocalized with SGs in the presence of Ars with 85.5% of GFP-
VP35 positive cells harbouring SGs (Fig. 4A and C). 79.5% of GFP-
VP35 expressing cells were positive for SGs after 6 h (Fig. 4A and C). At
12 h post-transfection, the number of cells containing SGs further
decreased to 37.2% as the concentration of GFP-VP35 continued to
increase (Fig. 4A and C). After reaching a threshold of VP35 expres-
sion, the percentage of cells containing SGs signiﬁcantly dropped to
17.2% at 24 h and GFP-VP35 appeared diﬀusely cytoplasmic (Fig. 4A
and C). These data indicate that EBOV VP35 requires a threshold of
viral protein expression to block SGs assembly.
3.6. EBOV VP35 interacts with SG components
Many viruses have evolved to disrupt RNA granules through the
cleavage of key host factor, the manipulation of PKR activation or
redirecting SG components (Tsai and Lloyd, 2014). To begin the
characterization of a possible mechanism behind EBOV-mediated SG
blockade, we co-transfected Vero cells with G3BP1-GFP or TIA-1-HA
and MYC or MYC-VP35 and cell lysates were immunoprecipitated
Fig. 2. EBOV VP35 blocks SG assembly independent of eIF2α phosphorylation. (A) Vero cells were transfected with GFP or GFP-VP35 and stressed without or with 500 μM Ars for 1 h.
Cell lysates were subjected to SDS-PAGE, immunoblotted and probed with the indicated antibodies. (B) Densitometry quantiﬁcation of phospho-eIF2α was determined by ImageJ
analysis. Values presented in the graph are normalized against the total amount of eIF2α in the cell lysate and represent fold change with the untreated GFP-transfected cells being
arbitrarily set to 1. (C) Vero cells transfected with GFP or GFP-VP35 were untreated or incubated with 50 nM PatA for 1 h. Cells were stained for G3BP1 (red) and eIF3 (cyan). Yellow
arrowheads indicate VP35-negative cells, while pink arrowheads show GFP-expressing cells. Scale bars are 10 µm. (D) Quantiﬁcation of cells exhibiting SGs derived from results shown
in Panel 2 C. Error bars represent the standard deviation from three independent experiments with at least 150 cells counted per treatment. Asterisks represent statistically signiﬁcant
diﬀerence between GFP and GFP-VP35-expressing cells (Two-way ANOVA; p < 0.001).
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using anti-MYC antibodies. G3BP1-GFP, but not TIA-1-HA, was pulled
down with VP35 (Fig. 5A). Additionally, eEF2 and eIF3 were found to
exclusively associate with MYC-VP35 and not the tag alone (Fig. 5A).
Overexpression of many SG-associated proteins, including TIA-1/TIAR
and G3BP1 induce the spontaneous SG assembly in the absence of
additional stress (Gilks et al., 2004; Tourriere et al., 2003). We
determined that VP35 was able to block the assembly of TIA-1-RFP
or G3BP1-GFP induced SGs (Fig. 5B and C).
To evaluate whether VP35 is capable to associate with SG compo-
nents in the absence of stress signals, co-immunoprecipitation experi-
ments were performed with lysates prepared from GFP- or GFP-VP35-
transfected Vero cells in the presence and absence of Ars stress using
anti-GFP beads. As shown in Fig. 5D, we demonstrated that the SG
components, eEF2, eIF3 (Jain et al., 2016) as well as G3BP1, interacted
with GFP-VP35 but not GFP alone, regardless of the absence or
presence of Ars stress. Additionally, the interactions were not depen-
dent upon RNA, as eEF2, eIF3 and G3BP1 still co-immunoprecipitated
in the presence of RNAse (Fig. 5D).
All together these results indicate that EBOV VP35 is capable of
associating with a number of SG components regardless of an external
stress or RNA, and supports the hypothesis that VP35 blocks SG
formation by recruiting fundamental SG components.
Fig. 3. EBOV VP35 blocks Se-induced SGs. (A) U2OS GFP-G3BP1-expressing cells transfected with pcDNA3.1 or MYC-VP35 were untreated or incubated with 1 mM Se for 2 h. Cells
were stained for TIAR (blue) and VP35 (red). Yellow arrowheads indicate VP35-negative cells, while pink arrowheads show VP35-expressing cells. Scale bars are 10 µm. (B)
Quantiﬁcation of cells exhibiting SGs derived from results shown in Panel 3 A. Error bars represent the standard deviation from three independent experiments with at least 150 cells
counted per treatment. Asterisks represent statistically signiﬁcant diﬀerence between mock or MYC-VP35-expressing cells in the presence of Se (Two-way ANOVA; p < 0.001).
Fig. 4. Blockade of Ars-induced SGs requires a threshold concentration of GFP-VP35. (A) Vero cells were transfected with GFP or GFP-VP35 for the indicated times and treated with
500 μM Ars for 1 h before ﬁxation. Cells were stained for SGs using antibodies against G3BP (red) and TIAR (cyan). Yellow arrowheads indicate VP35-negative cells, while pink
arrowheads show VP35-expressing cells. Bar, 10 µm. (B) Cell lysates from Vero cells transfected with GFP or GFP-VP35 were collected at the indicated times. Western blot analysis was
preformed with antibodies against GFP and GAPDH. (C) Quantiﬁcation of cells exhibiting SGs derived from results shown in Panel 4 A. Error bars represent the standard deviation from
three independent experiments with at least 150 cells counted per treatment. Asterisks represent statistically signiﬁcant diﬀerence between early times (3 and 6 h) post-transfection and
24 h post-transfection (Two-way ANOVA; p < 0.001).
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Considering that diﬀerent viruses interact with G3BP1 during SGs
assembly and/or blockade (Panas et al., 2012; Reineke and Lloyd,
2013; Valiente-Echeverria et al., 2014), we further investigated the
nature of VP35 and G3BP1 interplay. Proximity ligation assay (PLA)
produces distinct countable spots that represent a single-molecule
protein interaction < 40 nm apart (Jarvius et al., 2007; Soderberg
et al., 2006). In cells co-transfected with GFP-G3BP1 and MYC-VP35,
we conﬁrmed a close localization between G3BP1 and VP35 (53.3 ± 6.6
Fig. 5. EBOV VP35 interacts with multiple SG components. (A) Vero cells were transfected with G3BP1-GFP or TIA-1-HA and MYC or MYC-VP35 for 24 h. Cell lysates were collected
and subjected to anti-MYC immunoprecipitation. VP35-associated proteins were processed for Western blotting and probed for GFP, HA, MYC, eEF2 and eIF3. Data shown is
representative of three independent experiments. (B) Vero cells were transfected with TIA-1-RFP and GFP or GFP-VP35 for 24 h. Yellow arrowheads indicate VP35-negative cells, while
pink arrowheads show GFP-expressing cells. Scale bars are 10 µm. (C) Vero cells were transfected with G3BP1-GFP and MYC or MYC-VP35 for 24 h. Yellow arrowheads indicate VP35-
negative cells, while pink arrowheads show MYC-expressing cells. Scale bars are 10 µm. (D) Vero cells were transfected with GFP or GFP-VP35 and left untreated or treated with 500 μM
Ars for 1 h. Cell lysates were collected and subjected to anti-GFP immunoprecipitation in the absence of presence of RNAse A. VP35-associated proteins were processed for Western
blotting and probed for GFP, eEF2, eIF3 and G3BP1. Data shown is representative of three independent experiments. (E) G3BP1-GFP and MYC or MYC-VP35 co-transfected Vero cells
were ﬁxed, permeabilized, and incubated with anti-mouse MYC and anti-rabbit GFP. MYC-VP35/G3BP1-GFP heterodimers were visualized through incubation with PLA probes. Each
red dot corresponds to a single interaction event between VP35 and G3BP1. Nuclei were stained with DAPI (blue). Images shown are representative of at least 60 cells. (F) The graph
indicates the number of spots per cell ± SEM from E. Asterisks represent statistically signiﬁcant diﬀerence (unpaired t-test; p < 0.001). (G) GST-G3BP1 was incubated with GST
SpinTrap columns in the presence of absence of VP35-HIS. After washing extensively, the proteins bound to the beads were detected by Western blotting analysis using anti-G3BP1 and
anti-HIS antibodies.
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spots), whereas there was little signal detected upon transfection of
GFP-G3BP1 together with MYC tag only (5.1 ± 0.5 spots) (Fig. 5E and
F). However, in vitro GST-pull down using recombinant G3BP1-GST
(rG3BP1) and His-VP35 (rVP35) proteins revealed that rG3BP1 and
rVP35 were unable to interact directly with each other (Fig. 4G). These
results indicate that the G3BP1-VP35 interaction is indirect and
requires another host factor(s) or only takes place under physiological
conditions within a host cell.
3.7. The C-terminal of VP35 is necessary for inhibition of SG
formation
VP35 has an N-terminal coiled-coil domain (amino acids 83–118),
which is required for viral replication and nucleocapsid formation
(Reid et al., 2005) and a C-terminal IID (amino acids 221–340)
necessary for binding dsRNA and is suﬃcient for IFN inhibition
(Basler et al., 2003; Cardenas et al., 2006; Hartman et al., 2004). To
determine which domain of VP35 is required to block SG assembly, we
transfected Vero cells with a series of HA-tagged N- and C-terminal
VP35 truncations (Fig. 6A) and stressed with Ars. The N-terminal VP35
truncations, 40–340 and 80–340 had SGs in 24% and 14.7% of cells,
respectively, and were found to associate and surround SGs upon
treatment with Ars (Fig. 6B and C). Interestingly, constructs 120–340,
150–340 and 219–340 displayed a completely diﬀuse localization
throughout the cytoplasm and visible SGs were present in 18.7%,
30% and 31% of cells, respectively (Fig. 6B and C). Deletion of the C-
terminal domain (219–340) appeared to have a detrimental eﬀect on
the SG blockade, with 52.2%, 52.5%, 45.5% and 40.3% of cells
expressing the truncation mutants 1–80, 1–120, 1–150 and 1–219
having SGs, respectively, but did not reach the 77% of mock-trans-
Fig. 6. The EBOV VP35 C-terminal domain is necessary for eﬃcient SG clearance. (A) Vero cells were transfected with each of the indicated VP35 N- or C-terminal truncation mutants
for 24 h. Cell lysates were collected, processed for Western blotting and probed for using anti-HA and actin antibodies. (B) Vero cells were transfected with each of the indicated VP35 N-
or C-terminal truncation mutants for 24 h and left untreated (not shown) or treated with 500 μM Ars for 1 h. Cells were stained for HA (green), G3BP1 (red) and eIF3 (cyan). Yellow
arrowheads indicate non-transfected cells, while pink arrowheads show VP35-expressing cells. Scale bars are 10 µm. Insets are individual channels on the boxed region. (C) Schematic
diagram of HA-tagged VP35 N- or C-terminal truncation mutants. Quantiﬁcation of cells exhibiting SGs derived from results shown in Panel 6 B. Error bars represent the standard
deviation from three independent experiments with at least 150 cells counted per treatment.
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fected cells displaying SGs (Fig. 6B and C). We interpret this observa-
tion to suggest that the C-terminal domain of VP35 is required for the
eﬃcient inhibition of SG assembly. To link the binding of a particular
SG component (eEF2, eIF3 or G3BP1) to a domain of VP35, we
attempted to perform immunoprecipitations with the VP35 truncation
mutants. Although the HA-tagged constructs (VP35 full length and
truncations) were successfully pulled-down, non-speciﬁc binding of
SG-marker speciﬁc proteins (e.g., G3BP1, eIF3 & eEF2) to the HA-
beads rendered this experiment inconclusive (data not shown).
4. Discussion
A common feature of many RNA viruses is the transient induction
of SG (Lloyd, 2013), which is triggered early upon generation of dsRNA
replication intermediates, causing the activation of PKR and phosphor-
ylation of eIF2α. Here, we demonstrate that ZEBOV trVLP infection
does not induce the assembly of SGs itself but does block SG assembly
induced by oxidative stress. These data are in agreement with a
recently published study that performed EBOV infection of U2OS cells
under BSL4 containment (Nelson et al., 2016). In our study, we
demonstrate that EBOV VP35 is capable of blocking the assembly of
both canonical and non-canonical SG induced by diﬀerent kinds of
stress, including that induced by Ars, PatA, Se and by the over-
expression of TIA-1 or G3BP1, but not of those induced by PV
infection. Moreover we demonstrated that EBOV VP35 pulls down
diﬀerent SG markers and indirectly, binds to G3BP1. Finally, the
studies in which we employ VP35 truncation mutants suggest that the
C-terminal region is required for inhibition of SG assembly.
The severe haemorrhagic fever caused by EBOV is characterized by
early dysregulation of the host innate immune response through the
sequestration of dsRNA by VP35. VP35 blocks PKR activation through
its C-terminal IID by antagonizing and reversing PKR phosphorylation
(Feng et al., 2007; Schumann et al., 2009). In untreated cells, there
consistently appeared to be fewer cells with SGs and less phospho-
eIF2α in those cells expressing VP35, which may be due to its activity
on PKR. Yet, upon Ars stress the phosphorylation status of eIF2α was
not reversed by VP35 (Fig. 2A and B) and instead suggests a
mechanism of SG blockade that is eIF2α-independent. Moreover,
VP35 does not appear to block SG assembly through the degradation
of G3BP1, which is the case for PV at later times during infection
(White et al., 2007) (Fig. 3D). Interestingly, VP35 is not able to
counteract PV-triggered SG assembly (Supp. Fig. 1), which are
compositionally distinct from the ones induced by oxidative stress, or
heat shock, recruiting Sam68 but lacking eIF4G, PABP, and G3BP at
later times (Piotrowska et al., 2010; White and Lloyd, 2011). It is
possible that the diﬀerences in composition and mechanism of
assembly of PV-induced SG granules displace key VP35-interacting
partners and that the VP35 ability to block SG assembly is impaired in
these conditions.
In SG-positive cells expressing low concentrations of VP35, we
detected a distinct association of this viral protein with SGs (Figs. 1, 2
and 3). Taken together with the co-immunoprecipitation of multiple SG
components with VP35 (Fig. 3A and D), we propose that a possible
mechanism of SG dissolution relies on a VP35-mediated sequestration
of a host protein that leads to a reduction in the number of SGs and a
blockade in the host cell's ability to assemble new SGs with viral
mRNAs. As the nucleation of SGs is driven by G3BP1 is response to
stress (Tourriere et al., 2003), many viruses that induce SGs during
infection have evolved countermeasures by targeting G3BP1 (Reineke
and Lloyd, 2013). Several host and viral proteins containing an FGDF
motif have been shown to interact with G3BP1 (Panas et al., 2015),
although EBOV VP35 lacks this exact motif this does not strictly rule
out binding as HIV-1 Gag also lacks this motif yet binds G3BP1 directly
(Valiente-Echeverria et al., 2014). For example, diﬀerent alphavirus
non-structural proteins colocalize and co-immunoprecipitate with
G3BP1 to sequester it in viral replication complexes (Cristea et al.,
2006; Fros et al., 2012; Gorchakov et al., 2008; Panas et al., 2012).
Here we clearly demonstrate that EBOV VP35 interacts with G3BP1 in
co-immunoprecipitations and PLA; nevertheless, in vitro GST pull-
down binding assays demonstrate that the interaction is likely to be
indirect and may require another host factor or more physiological
conditions (Fig. 5). Moreover, we observed a strong co-localization of
G3BP1 and VP35 when both are diﬀusely distributed in the cytoplasm,
supporting the hypothesis that VP35 blocks SG formation by recruiting
fundamental SG components. Consistently, during trVLP infection SG
components, such as TIAR (Fig. 1A), co-localize with EBOV VP35 in
cytoplasmic aggregates, which are likely to be viral inclusion bodies
(Nanbo et al., 2013) and may suggest that EBOV requires G3BP1 for
replication similarly to Chikungunya virus that requires G3BP1 and
G3BP2 to facilitate a switch from early to late stages of replication
(Panas et al., 2015).
The HIV-1 structural protein Gag has been shown to interact with
G3BP1 and eEF2 to dissolve SGs, which is critical for the block to SG
assembly (Ohn et al., 2008; Valiente-Echeverria et al., 2014). HIV-1
also appears to be able to dissolve other forms of SGs such as those
induced by selenite but through a mechanism that does not require
eEF2 binding but instead aﬀects the association of hypophosphorylated
4EBP1 to the mRNA cap to allow continued translation of Gag (Cinti
et al., 2016; Emara et al., 2012). eEF2 is an important component in
translation elongation and its phosphorylation enhances shutoﬀ of
mRNA translation in response to stress (Patel et al., 2002). Indeed, we
have shown that VP35 co-immunoprecipitated with eEF2, however, we
were unable to determine whether or not VP35 required eEF2 for SG
repression. In Ars-treated, GFP-expressing cells, knockdown of eEF2
resulted in approximately 3% of cells having SGs (data not shown).
This low percentage of SG positive cells made it diﬃcult to conclude
any additional eﬀect of EBOV VP35 on SG blockade (data not shown).
The canonical SG component eIF3 was also speciﬁcally pulled down by
VP35 but did not appear to be essential for SG blockade as Se-induced
SGs, that characteristically lack eIF3 (Fujimura et al., 2012), were still
dissolved by the viral protein (Fig. 3). 100 host genes have been
identiﬁed as being involved in SG assembly (Jain et al., 2016; Ohn
et al., 2008), all of these serving to restrict or reprogram host gene
expression predominantly to the disadvantage of the virus. More
extensive work will be required to determine the exact mechanism of
SG repression by EBOV VP35 and whether or not G3BP1/eEF2 binding
is required for this activity.
The ability of EBOV VP35 to block SG assembly appeared to
require, at least in part, its C-terminal region of which several high
resolution structures are available (Leung et al., 2009, 2010a, 2010b).
This domain contains important clusters of conserved basic residues
necessary for protein-protein and protein-RNA interactions (Hastie
et al., 2012). Although, we demonstrate that RNA does not mediate the
interaction between eEF2 and eIF3 (Fig. 5D), the C-terminal domain of
VP35 appears, at least in part, to be necessary for SG blockade (Fig. 6).
Interestingly, amino acids 80–120, which contain the coiled coil
domain, were not required for SG dissolution yet appeared to be
necessary for the association to SGs in the presence of Ars but only in
the context of the C-terminal domain (Fig. 6). This result suggests that
the coiled coil domain may be necessary for binding to a particular SG
component. More work will be required to clarify this point.
Recently published work complements the work presented here in
that Nelson et al., using several of the techniques used herein, showed
that VP35 subverts the host stress response by preventing type I SG
assembly (Nelson et al., 2016), whereby threshold levels of VP35 were
necessary to elicit this eﬀect, similar to the conclusions reached here
(Fig. 4). Likewise, VP35 coaggregated with several SG proteins includ-
ing eIF3, eIF4G, PABP and TIAR (Nelson et al., 2016 and this work) in
cytoplasmic inclusion bodies. Nevertheless, our work both comple-
ments and extends the study. For example, we demonstrate that VP35
blocks type II SGs that assemble via alternative mechanisms (Cinti
et al., 2016; Fujimura et al., 2012). In addition, we employed in vitro
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GST-pulldown as well as in situ (live cell) interaction assays to
demonstrate interactions between VP35 with SG components
(Fig. 5). Finally, we mapped the domain of VP35 that elicits the SG
blockade to the C-terminal domain, a domain that binds double-
stranded RNA (dsRNA) and antagonizes type I IFN responses and
that therefore likely mediate innate responses to infection (Fig. 6).
Nelson et al. also used an RNA binding point mutants of VP35 to
determine if this activity was required. In the work presented here, a
more severe truncation mutant lost the ability to suppress SG
assembly, while full length VP35 did not require RNA to associate to
SG components G3BP-1, eIF2 and eIF3, indicating that the inherent
RNA-binding domain of VP35 may not be an absolute requirement for
the SG blockade but may also require contributions of other VP35
domains.
In conclusion, we describe a novel activity of EBOV VP35 and
another mechanism by which this viral protein inhibits the host innate
immune response to block SG assembly when cells are exposed to
diﬀerent stressors. This work represents yet another example of an
RNA virus that encodes a limited number of genes and that has evolved
a mechanism to control SG assembly/function to potentially foster a
productive replication environment.
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